Jotam G Pasipanodya1, Wynand Smythe2, Corinne S Merle3,4, Piero L Olliaro4, Devyani Deshpande1, Gesham Magombedze1, Helen McIlleron2, Tawanda Gumbo1. 1. Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas. 2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, South Africa. 3. Faculty of Epidemiology and Population Health, Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, United Kingdom. 4. Special Programme on Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland.
Abstract
Background: In the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK variability played a role in patient outcomes. Methods: Patients recruited in the trial were followed for 24 months, and relapse ascertained using spoligotyping. Blood was drawn for drug concentrations on 2 separate days during the first 2 months of therapy, and compartmental PK analyses was performed. Failure to attain sustained sputum culture conversion at the end of treatment, relapse, or death during follow-up defined therapy failure. In addition to standard statistical analyses, we utilized an ensemble of machine-learning methods to identify patterns and predictors of therapy failure from among 27 clinical and laboratory features. Results: Of 126 patients, 95 (75%) had favorable outcomes and 19 (15%) failed therapy, relapsed, or died. Pyrazinamide and rifampicin peak concentrations and area under the concentration-time curves (AUCs) were ranked higher (more important) than gatifloxacin AUCs. The distribution of individual drug concentrations and their ranking varied significantly between South African and West African trial sites; however, drug concentrations still accounted for 31% and 75% of variance of outcomes, respectively. We identified a 3-way antagonistic interaction of pyrazinamide, gatifloxacin, and rifampicin concentrations. These negative interactions disappeared if rifampicin peak concentration was above 7 mg/L. Conclusions: Concentration-dependent antagonism contributed to death, relapse, and therapy failure but was abrogated by high rifampicin concentrations. Therefore, increasing both rifampin and gatifloxacin doses could improve outcomes. Clinical Trials Registration: NCT00216385.
RCT Entities:
Background: In the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK variability played a role in patient outcomes. Methods:Patients recruited in the trial were followed for 24 months, and relapse ascertained using spoligotyping. Blood was drawn for drug concentrations on 2 separate days during the first 2 months of therapy, and compartmental PK analyses was performed. Failure to attain sustained sputum culture conversion at the end of treatment, relapse, or death during follow-up defined therapy failure. In addition to standard statistical analyses, we utilized an ensemble of machine-learning methods to identify patterns and predictors of therapy failure from among 27 clinical and laboratory features. Results: Of 126 patients, 95 (75%) had favorable outcomes and 19 (15%) failed therapy, relapsed, or died. Pyrazinamide and rifampicin peak concentrations and area under the concentration-time curves (AUCs) were ranked higher (more important) than gatifloxacin AUCs. The distribution of individual drug concentrations and their ranking varied significantly between South African and West African trial sites; however, drug concentrations still accounted for 31% and 75% of variance of outcomes, respectively. We identified a 3-way antagonistic interaction of pyrazinamide, gatifloxacin, and rifampicin concentrations. These negative interactions disappeared if rifampicin peak concentration was above 7 mg/L. Conclusions: Concentration-dependent antagonism contributed to death, relapse, and therapy failure but was abrogated by high rifampicin concentrations. Therefore, increasing both rifampin and gatifloxacin doses could improve outcomes. Clinical Trials Registration: NCT00216385.
Authors: Emmanuel Chigutsa; Jotam G Pasipanodya; Marianne E Visser; Paul D van Helden; Peter J Smith; Frederick A Sirgel; Tawanda Gumbo; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2014-10-13 Impact factor: 5.191
Authors: Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191
Authors: Oren Gordon; Donald E Lee; Bessie Liu; Brooke Langevin; Alvaro A Ordonez; Dustin A Dikeman; Babar Shafiq; John M Thompson; Paul D Sponseller; Kelly Flavahan; Martin A Lodge; Steven P Rowe; Robert F Dannals; Camilo A Ruiz-Bedoya; Timothy D Read; Charles A Peloquin; Nathan K Archer; Lloyd S Miller; Kimberly M Davis; Jogarao V S Gobburu; Sanjay K Jain Journal: Sci Transl Med Date: 2021-12-01 Impact factor: 17.956
Authors: Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain Journal: Nat Med Date: 2020-02-17 Impact factor: 53.440
Authors: Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079
Authors: Alvaro A Ordonez; Elizabeth W Tucker; Carolyn J Anderson; Claire L Carter; Shashank Ganatra; Deepak Kaushal; Igor Kramnik; Philana L Lin; Cressida A Madigan; Susana Mendez; Jianghong Rao; Rada M Savic; David M Tobin; Gerhard Walzl; Robert J Wilkinson; Karen A Lacourciere; Laura E Via; Sanjay K Jain Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Doctor B Sibandze; Beki T Magazi; Lesibana A Malinga; Nontuthuko E Maningi; Bong-Akee Shey; Jotam G Pasipanodya; Nontombi N Mbelle Journal: BMC Infect Dis Date: 2020-07-31 Impact factor: 3.090